08HH logo

Shanghai Fosun Pharmaceutical (Group) DB:08HH Stock Report

Last Price

€1.70

Market Cap

€8.2b

7D

0.2%

1Y

-11.0%

Updated

06 Dec, 2024

Data

Company Financials +

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

DB:08HH Stock Report

Market Cap: €8.2b

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Shanghai Fosun Pharmaceutical (Group)
Historical stock prices
Current Share PriceCN¥1.70
52 Week HighCN¥2.32
52 Week LowCN¥1.29
Beta0.72
11 Month Change-4.33%
3 Month Change28.55%
1 Year Change-11.03%
33 Year Change-58.84%
5 Year Changen/a
Change since IPO-58.89%

Recent News & Updates

Recent updates

Shareholder Returns

08HHDE PharmaceuticalsDE Market
7D0.2%-0.1%3.2%
1Y-11.0%-13.3%9.7%

Return vs Industry: 08HH exceeded the German Pharmaceuticals industry which returned -14.7% over the past year.

Return vs Market: 08HH underperformed the German Market which returned 10.1% over the past year.

Price Volatility

Is 08HH's price volatile compared to industry and market?
08HH volatility
08HH Average Weekly Movement11.2%
Pharmaceuticals Industry Average Movement5.9%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.5%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 08HH's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 08HH's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
199439,309Deyong Wenwww.fosunpharma.com

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. The company’s product pipeline includes HLX15, a recombinant anti-CD38 human monoclonal antibody injection for treatment of multiple myeloma; HLX13, an anti-CTLA-4 human monoclonal antibody for the treatment of melanoma, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, malignant pleural mesothelioma, and esophageal squamous cell cancer; SZEY-2108 for the treatment of carbapenem resistant enterobacteriaceae (CRE) infection; XH-S003 for the treatment of IgA nephropathy and other glomerular diseases; HLX43, an antibody-drug for the treatment of metastatic solid tumors; XS-03 for the treatment of RAS-mutated advanced solid tumor; OP0595, a nacubactam for the treatment of aerobic gram-negative bacteria; XH-S002 for the treatment of ischemic stroke and transient ischemic attack which are in Phase I; HLX26, anti-LAG-3 humanized monoclonal antibody injection for the treatment of metastatic colorectal cancer; FCN-338 for the treatment of myeloid malignancies; FCN-159 for the treatment of langerhans cell histiocytosis; HLX208, a BRAF V600E inhibitor for the treatment of non-small cell lung cancer which are in phase II; FS-1502, a HER2 humanized monoclonal antibody-monomethyl auristatin F injection for the treatment of HER2-positive locally advanced or metastatic breast cancer; FCN-159 for the treatment of neurofibromatosis; ET-26, a methoxyetomidate hydrochloride for the treatment of general anesthesia which are in phase III.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Fundamentals Summary

How do Shanghai Fosun Pharmaceutical (Group)'s earnings and revenue compare to its market cap?
08HH fundamental statistics
Market cap€8.22b
Earnings (TTM)€275.28m
Revenue (TTM)€5.42b

33.2x

P/E Ratio

1.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
08HH income statement (TTM)
RevenueCN¥41.61b
Cost of RevenueCN¥21.83b
Gross ProfitCN¥19.78b
Other ExpensesCN¥17.67b
EarningsCN¥2.11b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.79
Gross Margin47.55%
Net Profit Margin5.08%
Debt/Equity Ratio55.0%

How did 08HH perform over the long term?

See historical performance and comparison

Dividends

1.0%

Current Dividend Yield

34%

Payout Ratio